MaxLinear (MXL) has had the highest return since January 1, 2026 and this year by a mid-cap US stock, returning 439.3%.
| ASSET | % RETURN |
|---|---|
MaxLinear (MXL) | 439.32% |
Iovance Biotherapeutics (IOVA) | 425.9% |
Erasca (ERAS) | 332.08% |
Aehr Test Systems (AEHR) | 302.66% |
AXT (AXTI) | 298.02% |
Pulse Biosciences (PLSE) | 289.08% |
Veradermics (MANE) | 285% |
Penguin Solutions (PENG) | 283.7% |
Abcellera Biologics (ABCL) | 266.81% |
Kodiak Sciences (KOD) | 257.83% |
CareDx (CDNA) | 237.95% |
Okeanis Eco Tankers (ECO) | 230.71% |
Hyperliquid Strategies Inc Common Stock (PURR) | 214.73% |
PBF Energy (PBF) | 214.04% |
Ichor (ICHR) | 212.19% |
Applied Opt (AAOI) | 201.66% |
Calumet Specialty Products Partners (CLMT) | 185.38% |
International Seaways (INSW) | 185% |
Cohu (COHU) | 184.84% |
Silicon Motion Technology (SIMO) | 181.32% |
Ringcentral (RNG) | 174.91% |
Iridium Communications (IRDM) | 174.35% |
Definium Therapeutics (DFTX) | 173.33% |
Oruka Therapeutics (ORKA) | 170.9% |
Tango Therapeutics (TNGX) | 169.04% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.